Entera Bio Ltd (ENTX): Price and Financial Metrics

Entera Bio Ltd (ENTX): $0.67

0.00 (0.39%)

POWR Rating

Component Grades













Add ENTX to Watchlist
Sign Up

Industry: Biotech



in industry

ENTX Stock Summary

  • ENTX's price/sales ratio is 68.74; that's higher than the P/S ratio of 97.09% of US stocks.
  • With a year-over-year growth in debt of -60.24%, ENTERA BIO LTD's debt growth rate surpasses just 4.05% of about US stocks.
  • Revenue growth over the past 12 months for ENTERA BIO LTD comes in at -54.55%, a number that bests just 3.39% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ENTERA BIO LTD are PSNL, DYAI, TARS, SDGR, and VLDR.
  • ENTX's SEC filings can be seen here. And to visit ENTERA BIO LTD's official web site, go to www.enterabio.com.

ENTX Valuation Summary

  • ENTX's EV/EBIT ratio is -1.2; this is 113.95% lower than that of the median Healthcare stock.
  • ENTX's price/sales ratio has moved NA NA over the prior 54 months.

Below are key valuation metrics over time for ENTX.

Stock Date P/S P/B P/E EV/EBIT
ENTX 2022-11-25 71.6 1.4 -4.0 -1.2
ENTX 2022-11-23 71.9 1.4 -4.0 -1.2
ENTX 2022-11-22 68.1 1.4 -3.8 -1.0
ENTX 2022-11-21 71.2 1.4 -4.0 -1.2
ENTX 2022-11-18 70.9 1.4 -3.9 -1.2
ENTX 2022-11-17 68.8 1.4 -3.8 -1.1

ENTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ENTX has a Quality Grade of F, ranking ahead of 3.86% of graded US stocks.
  • ENTX's asset turnover comes in at 0.032 -- ranking 348th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ENTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.032 0.521 5.412
2021-03-31 0.039 0.531 4.464
2020-12-31 0.032 0.427 4.177
2020-09-30 0.039 0.588 4.010
2020-06-30 0.032 0.453 4.665
2020-03-31 0.023 0.094 3.818

ENTX Price Target

For more insight on analysts targets of ENTX, see our ENTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.00 Average Broker Recommendation 1.5 (Moderate Buy)

ENTX Stock Price Chart Interactive Chart >

Price chart for ENTX

ENTX Price/Volume Stats

Current price $0.67 52-week high $3.51
Prev. close $0.67 52-week low $0.47
Day low $0.67 Volume 17,000
Day high $0.69 Avg. volume 77,116
50-day MA $0.81 Dividend yield N/A
200-day MA $1.69 Market Cap 19.38M

Entera Bio Ltd (ENTX) Company Bio

Entera Bio Ltd operates as a biotechnology company. The Company specializes in the oral delivery of molecules and biologics. Entera Bio also develops candidates for the treatment of osteoporosis. Entera Bio serves patients in the United States and Israel.

ENTX Latest News Stream

Event/Time News Detail
Loading, please wait...

ENTX Latest Social Stream

Loading social stream, please wait...

View Full ENTX Social Stream

Latest ENTX News From Around the Web

Below are the latest news stories about ENTERA BIO LTD that investors may wish to consider to help them evaluate ENTX as an investment opportunity.

New Strong Buy Stocks for November 16th

ENTX, STIM, FN, ANGN and FUTU have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2022.

Yahoo | November 16, 2022

H.C. Wainwright Remains a Buy on Entera Bio (ENTX)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Entera Bio (ENTX - Research Report) today and set a price target of $10.00. The company's shares closed last Friday at $0.50.Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Genmab, and Equillium. According to TipRanks, Selvaraju has an average return of -28.1% and a 23.26% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Entera Bio with a $6.00 average price target, a 1,100.00% upside from current levels.

Christine Brown on TipRanks | November 14, 2022

Entera Bio Ltd. (ENTX) Reports Q3 Loss, Misses Revenue Estimates

Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 31.25% and 88.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial results for the third quarter of 2022 and provided the following corporate updates. Corporate Updates: Achieved FDA Agreement for Pivotal Study of EB613, the World’s First Daily Bone Forming Oral PTH Tablet On October 6th, 2022, Entera announced that it had successfully completed i

Yahoo | November 10, 2022

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis

- Total Hip BMD Established as Primary Endpoint -JERUSALEM, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced today the successful conclusion of its Type C meeting and agreement from the U.S. Food and Drug Administration (FDA) that a single Phase 3 placebo-controlled study could support a New Drug Application (NDA) submission of EB613 (oral hPTH (1-34), teripar

Yahoo | October 6, 2022

Read More 'ENTX' Stories Here

ENTX Price Returns

1-mo -0.45%
3-mo -52.14%
6-mo -67.00%
1-year -78.73%
3-year -69.41%
5-year N/A
YTD -76.20%
2021 160.65%
2020 -49.53%
2019 -29.84%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7058 seconds.